Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lens implant aims to sharpen sight after cataracts

NCT ID NCT07502456

Disease control Sponsor: Alcon Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new type of artificial lens, called the Clareon TruPlus, for people having cataract surgery. The lens is placed inside the eye to replace the cloudy natural lens and help restore clear vision. About 122 adults with cataracts and astigmatism will receive the implant in both eyes. The goal is to check how well the lens works and if it is safe over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Clareon TruPlus intraocular lens (IOL) implant
What this could lead to
If successful, this could provide a new option for clear distance vision after cataract surgery, with a slightly extended depth of focus compared to standard lenses.
What could go wrong
This is a small, early-stage study with no control group, so results may not apply to everyone. Risks include typical surgical complications like infection or lens dislocation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 122 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Diagnosed with bilateral cataracts and planned bilateral cataract extraction by routine phacoemulsification. * Potential postoperative BCDVA of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator. * Astigmatism suitable for correction with available toric IOL models. * Other protocol-specified inclusion criteria may apply. Key Exclusion Criteria: * Age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and other eye conditions as specified in the protocol. * Moderate to severe dry eye that would affect study measurements. * Other protocol-specified exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aphakia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Aphakia astigmatism cataract congenital primary aphakia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aphakia Astigmatism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Berkeley Eye Center

    RECRUITING

    Sugar Land, Texas, 77478, United States

  • Carolina Eyecare Physicians LLC

    RECRUITING

    Mt. Pleasant, South Carolina, 29464, United States

  • Cleveland Eye Clinic

    RECRUITING

    Brecksville, Ohio, 44141, United States

  • Eye Doctors of Arizona

    RECRUITING

    Phoenix, Arizona, 85028, United States

  • The Eye Institute of Utah

    RECRUITING

    Salt Lake City, Utah, 84107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.